Key facts
- Innocens’s last known valuation is $5.5M (Nov 2025).
- It has raised $2.2M; the latest was Early Stage VC ($1.7M) in Nov 2025.
- Notable investors include LRM, Be Angels, Business Angels Network Vlaanderen, EIT Health, Nxt2b — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Innocens
- ·The full record, as it builds
Funding rounds
No funding rounds for Innocens are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Innocens
Developer of an AI software designed for clinicians to increase care efficiency in the neonatal ICU. The company's software regularly scans patients' data for the most subtle signs of sepsis, and this information is relayed to hospital staff, which allows them to have access to critical insights, helping clinicians to make informed clinical decisions.
- Sector
- Healthcare
- HQ
- Antwerp, Belgium
- Founded
- 2021
- Employees
- 6
- Website
- innocens.be/
- Ownership
- Privately Held (backing)
Innocens doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Innocens shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Innocens in its N-PORT filings yet. We sweep new filings monthly.